NCT01001130已完成不适用
An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance (PMS) to Monitor the Safety and Effectiveness of Avamys® Administered in Korean Patients According to the Prescribing Information
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 3,244
- 试验地点
- 1
- 主要终点
- Number of participants with an adverse event
研究概览
简要总结
Non-interventional, open-label, single group, multicentric post-marketing surveillance to monitor the safety and effectiveness of AVAMYS nasal spray administered in Korean patients according to the prescribing information.
AVAMYS is a registered trademark of the GSK group of companies.
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 2 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
fluticasone furoate group
Korean patients administered fluticasone furoate according to the Prescription information
干预措施: fluticasone furoate group (Drug)
结局指标
主要结局
Number of participants with an adverse event
时间窗: 2 weeks
Number of participants with an adverse event
次要结局
- Number of participants with a serious adverse event(2 weeks)
- Number of participants with an unexpected or expected adverse drug reaction(2 weeks)
- Effectiveness after AVAMYS nasal spray administration(2 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Regulatory Hycamtin(Oral) PMSLung Cancer, Small CellNCT01037023GlaxoSmithKline92
已完成
不适用
Regulatory TYKERB® Tablets PMSCancerNCT00975988GlaxoSmithKline750
已完成
不适用
An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and/or Efficacy of AVANDAMET Between June 2004 and January 2010Diabetes Mellitus, Type 2NCT01294553GlaxoSmithKline717
已完成
不适用
AVODART(Dutasteride) Post-marketing Surveillance(PMS)Prostatic HyperplasiaBenign Prostatic HyperplasiaNCT01299571GlaxoSmithKline3,977
已完成
不适用
Regulatory Nebilet PMSHypertensionHeart FailureNCT01077661GlaxoSmithKline743